• VBI and Syneos Health partner to prepare for commercial launch of VBI's 3-antigen hepatitis B vaccine in the U.S., Europe, and Canada, pending regulatory approvals
  • Syneos Health selected for their robust and innovative commercialization experience and deep vaccine expertise, including successful partnerships with leading vaccine manufacturers
  • The BLA was submitted to FDA (U.S.) on November 30, 2020 and the MAA was submitted to EMA (Europe) on November 20, 2020

Attachments

  • Original document
  • Permalink

Disclaimer

VBI Vaccines Inc. published this content on 07 December 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 07 December 2020 13:18:03 UTC